PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

Author： Hoeller Sylvia   Walz Christoph   Reiter Andreas   Dirnhofer Stephan   Tzankov Alexandar  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.1, 2011-01, pp. : 53-62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

JAK2 inhibitors in the treatment of myeloproliferative neoplasms

By Tibes Raoul   Bogenberger James M   Geyer Holly L   Mesa Ruben A  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 12, 2012-12 ,pp. : 1755-1774

Informa Healthcare

Access to resources Recommend Favorite

Targeting JAK2 in the therapy of myeloproliferative neoplasms

By Reddy Mamatha M   Deshpande Anagha   Sattler Martin  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 3, 2012-03 ,pp. : 313-324

Informa Healthcare

Access to resources Recommend Favorite

New JAK2 inhibitors for myeloproliferative neoplasms

By Quintáás-Cardama Alfonso   Verstovsek Srdan  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 7, 2011-07 ,pp. : 961-972

Informa Healthcare

Access to resources Recommend Favorite

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

By  

Current Medicinal Chemistry, Vol. 19, Iss. 26, 2012-09 ,pp. : 4399-4413

Bentham Science Publishers

Access to resources Recommend Favorite

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

By Rosenthal Allison   Mesa Ruben A  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 9, 2014-06 ,pp. : 1265-1276

Informa Healthcare

Access to resources Recommend Favorite